Company profile
KYNTRA BIO, INC.
NASDAQ:KYNBBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ROXADUSTAT | phase4 | — | 22 | completed, not_yet_recruiting, terminated, withdrawn |
| PAMREVLUMAB | phase3 | — | 17 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (41)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01181245 | phase1 | completed | 2008-12-01 | 2014-05-01 | Kyntra Bio | A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer |
| NCT00456053 | phase2 | completed | 2005-12-01 | — | Kyntra Bio | A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin |
| NCT01217632 | phase2 | terminated | 2010-08-01 | 2015-06-01 | Kyntra Bio | A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection |
| NCT06842498 | phase2 | recruiting | 2026-02-22 | 2028-03-31 | Kyntra Bio | A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
| NCT02210559 | phase1_2 | completed | 2014-07-31 | 2021-12-15 | Kyntra Bio | A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer |
FDA applications (0)
No records yet.